Get access

Feasibility of measuring prostate perfusion with arterial spin labeling



This article is corrected by:

  1. Errata: Feasibility of measuring prostate perfusion with arterial spin labeling Volume 26, Issue 10, 1338, Article first published online: 26 April 2013

  • Presented in part at the 19th Annual Meeting ISMRM, Montreal, QC, Canada, 2011.

G. Metzger, The University of Minnesota, 2021 Sixth Street SE, Minneapolis, MN 55455, USA.



Prostate perfusion has the potential to become an important pathophysiological marker for the monitoring of disease progression or the assessment of the therapeutic response of prostate cancer. The feasibility of arterial spin labeling, an MRI approach for the measurement of perfusion without an exogenous contrast agent, is demonstrated in the prostate for the first time. Although various arterial spin labeling methods have been demonstrated previously in highly perfused organs, such as the brain and kidneys, the prospect of obtaining such measurements in the prostate is challenging because of the relatively low blood flow, long transit times, susceptibility-induced image distortion and local motion. However, despite these challenges, this study demonstrates that, with a whole-body transmit coil and external receiver array, global prostate perfusion can be measured with arterial spin labeling at 3 T. In five healthy subjects with a mean age of 44 years, the mean total prostate blood flow was measured to be 25.8 ± 7.1 mL/100 cm3/min, with an estimated bolus duration and arterial transit time of 884 ± 209 ms and 721 ± 131 ms, respectively. Copyright © 2012 John Wiley & Sons, Ltd.

Get access to the full text of this article